Search by Drug Name or NDC

    NDC 71665-0001-02 CYFENDUS 100 ug/mL Details

    CYFENDUS 100 ug/mL

    CYFENDUS is a INTRAMUSCULAR INJECTION, SUSPENSION in the VACCINE category. It is labeled and distributed by Emergent Product Development Gaithersburg Inc.. The primary component is BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS.

    Product Information

    NDC 71665-0001
    Product ID 71665-001_9b03fee7-6174-4362-9b11-d4c069f3eb3d
    Associated GPIs
    GCN Sequence Number 085091
    GCN Sequence Number Description anthrax vaccine adsorbed, adjv VIAL 0.5ML/DOSE INTRAMUSC
    HIC3 W7N
    HIC3 Description TOXIN-PRODUCING BACILLI VACCINES/TOXOIDS
    GCN 54529
    HICL Sequence Number 049090
    HICL Sequence Number Description ANTHRAX VACCINE ADSORBED, ADJUVANTED
    Brand/Generic Brand
    Proprietary Name CYFENDUS
    Proprietary Name Suffix n/a
    Non-Proprietary Name Anthrax Vaccine Adsorbed, Adjuvanted
    Product Type VACCINE
    Dosage Form INJECTION, SUSPENSION
    Route INTRAMUSCULAR
    Active Ingredient Strength 100
    Active Ingredient Units ug/mL
    Substance Name BACILLUS ANTHRACIS STRAIN V770-NP1-R ANTIGENS
    Labeler Name Emergent Product Development Gaithersburg Inc.
    Pharmaceutical Class Actively Acquired Immunity [PE], Anthrax Vaccines [Chemical/Ingredient], Live Attenuated Bacillus Anthracis Vaccine [EPC], Vaccines, Attenuated [Chemical/Ingredient]
    DEA Schedule n/a
    Marketing Category BLA
    Application Number BLA125761
    Listing Certified Through 2024-12-31

    Package

    NDC 71665-0001-02 (71665000102)

    NDC Package Code 71665-001-02
    Billing NDC 71665000102
    Package 10 VIAL, MULTI-DOSE in 1 CARTON (71665-001-02) / 5 mL in 1 VIAL, MULTI-DOSE (71665-001-01)
    Marketing Start Date 2023-09-19
    NDC Exclude Flag N
    Pricing Information N/A